

Recombinant human HAPLN1 protein: a multi-functional therapeutic candidate to treat dry eye disease

HapInScience, Inc.



OPHTHALMOLOGY	Candidate
Product Type	Recombinant protein
Indication	Dry eye disease (DED)
Target	<ul style="list-style-type: none"> - Hyaluronan and proteoglycans - Modulation of CD44 signaling through formation of HAPLN1-containing aggregate by linking hyaluronic acid and proteoglycans
MoA (Mechanism of Action)	The recovery of the ocular surface homeostasis and corneal epithelium through CD44-mediated multiple suppression of the vicious cycle in DED
Competitiveness	First in Class <ul style="list-style-type: none"> - Mucin-enhancing effect through the increase in goblet cell number - Corneal epithelial wound healing - Anti-oxidative/anti-inflammatory/anti-senescence effects - Recovery of the tear volume, improvement of the tear film break-up time
Development Stage	Candidate
Route of Administration	Topical administration (eye drop)